Edoxaban outperforms edoxaban plus antiplatelet agent in patients with a-fib and stable coronary artery disease: Study

Published Date: 04 Sep 2024

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Doctors say lung cancer is still the deadliest cancer, but hope is growing

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

4.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

5.

Virtual Reality Travel Reduces Cancer Pain.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot